Navigation Links
Blocking key enzyme minimizes stroke injury, UT Southwestern research finds
Date:6/26/2014

DALLAS June 26, 2014 A drug that blocks the action of the enzyme Cdk5 could substantially reduce brain damage if administered shortly after a stroke, UT Southwestern Medical Center research suggests.

The findings, reported in the June 11 issue of the Journal of Neuroscience, determined in rodent models that aberrant Cdk5 activity causes nerve cell death during stroke.

"If you inhibit Cdk5, then the vast majority of brain tissue stays alive without oxygen for up to one hour," said Dr. James Bibb, Associate Professor of Neurology and Neurotherapeutics at UT Southwestern and senior author of the study. "This result tells us that Cdk5 is a central player in nerve cell death."

More importantly, development of a Cdk5 inhibitor as an acute neuroprotective therapy has the potential to reduce stroke injury.

"If we could block Cdk5 in patients who have just suffered a stroke, we may be able to reduce the number of patients in our hospitals who become disabled or die from stroke. Doing so would have a major impact on health care," Dr. Bibb said.

While several pharmaceutical companies worked to develop Cdk5 inhibitors years ago, these efforts were largely abandoned since research indicated blocking Cdk5 long-term could have detrimental effects. At the time, many scientists thought aberrant Cdk5 activity played a major role in the development of Alzheimer's disease and that Cdk5 inhibition might be beneficial as a treatment.

Based on Dr. Bibb's research and that of others, Cdk5 has both good and bad effects. When working normally, Cdk5 adds phosphates to other proteins that are important to healthy brain function. On the flip side, researchers have found that aberrant Cdk5 activity contributes to nerve cell death following brain injury and can lead to cancer.

"Cdk5 regulates communication between nerve cells and is essential for proper brain function. Therefore, blocking Cdk5 long-term may not be
'/>"/>

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Benaroya Research Institute evaluates immunology approach to blocking breast cancer
2. Blocking antioxidants in cancer cells reduces tumor growth in mice
3. Blocking signal-transmitting cellular pores may prevent damage to kidneys
4. Blocking the active site of thiolase
5. RxISK Drug Safety Petition Asks AbbVie and InterMune to Stop Blocking Access to Drug Clinical Trial Data
6. Blocking key enzyme in cancer cells could lead to new therapy
7. Mount Sinai Researchers Find that Blocking Sugar Intake May Reduce Cancer Risk or Progression in Obese and Diabetic People
8. Study shows additional role for abiraterone in blocking tumor growth in CRPC
9. Autism Speaks trailblazer study -- Blocking cell distress signals can ease autism symptoms
10. Evidence supports blocking immune response to enhance viral therapy against solid tumors
11. Researchers prevent cancer spread by blocking tissue scarring
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blocking key enzyme minimizes stroke injury, UT Southwestern research finds
(Date:5/4/2015)... California (PRWEB) May 04, 2015 In ... holistic treatment for substance absue, Per Wickstrom, the founder ... Entertainment’s EcoLuxe Lounge and the “Salute to the ... Stardust Penthouse on the top floor of the luxurious ... Los Angeles’ top producer of sustainable product placement in ...
(Date:5/4/2015)... New York (PRWEB) May 04, 2015 ... as $2.4 billion to settle thousands of Actos lawsuits ... diabetes medication increases the risk that a patient will ... on April 28th, if 95% of those eligible for ... resolve nearly 9,000 bladder cancer cases currently pending in ...
(Date:5/4/2015)... SAN DIEGO, California (PRWEB) May 04, 2015 ... health plans to manage their health is critical to ... patient satisfaction and reducing costs, but this will require ... spectrum. This change also demands that health systems move ... to speakers who took part in the third live ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to ... User Group (RUG) Conference in Baltimore, MD from May ... User Group provides an opportunity for clients to gather ... gallery. , In addition to sponsoring the event, TROY ... Atlantic RUG Conference. Attendees can stop by the TROY ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 The opportunity ... a full life are the motivating forces behind The Fairy ... clinical psychologist and author Amy L. Stark. , The inspiration ... little girl next door comes from Stark’s desire to be ... “I’ve been a fairy godmother to my neighbors’ children since ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2
... N.J., July 31 Smart Balance Inc.,(Nasdaq: ... organization,today. Richard McWilliams has been named to the ... reporting to Gregory Venner, executive,vice president and chief ... marketing efforts for the Company,s core brands., ...
... (NASDAQ: TOMO) announced today that it has extended its reach in ... installed in Scandinavia, at Lund University Hospital in Sweden. ... ... -- Jef Van Dam, general manager of TomoTherapyEMEA, said, "TomoTherapy ...
... July 31 HealthSouth,Corporation (NYSE: HLS ... wholly owned,subsidiaries, its previously announced purchase of ... inpatient rehabilitation hospital in,Vineland, NJ, from The ... of South Jersey, under the outstanding,leadership of ...
... are a common method for advertising food products. According ... food advertisements have a powerful influence on its viewers, ... adulthood has been shown to be a time for ... smoking and alcohol use and decreases in physical activity ...
... provides Aurora with technology and sensor standardization across ... facilities - creating efficiencies and cost savings, ... Pulse CO-Oximetry and Measure-Through-Motion-and-Low-Perfusion Pulse,Oximetry, announced that Aurora ... SET pulse oximetry technology. The integrated health,care provider ...
... CAMBRIDGE, Mass., July 31 HIV/AIDS and health ... as Director for the Health,Systems 20/20 project in ... of Global Health,s flagship project working to strengthen ... the financing,governance, operational, and capacity constraints to further ...
Cached Medicine News:Health News:Smart Balance Announces Marketing Organization Appointment 2Health News: Sweden to Receive Scandinavia's First TomoTherapy System : Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments 2Health News: Sweden to Receive Scandinavia's First TomoTherapy System : Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments 3Health News:HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital 2Health News:HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital 3Health News:Watching too much TV is causing some university students to pack on the pounds 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 5Health News:Ann Lion Coleman Joins Abt Associates to Direct USAID Health Systems 20/20 Project 2
(Date:5/4/2015)... 4, 2015 Bayer HealthCare (Bayer) has entered ... (NASDAQ: ISIS ) on ISIS-FXI Rx, an ... of thrombosis. Under the agreement Bayer will further develop ... unmet medical need. As part of the clinical development ... ISIS-FXI Rx in an appropriate patient community. ...
(Date:5/4/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) has ... (Bayer) to develop and commercialize ISIS-FXI Rx for ... agreement, Isis is eligible to receive up to $155 ... up-front payment and a $55 million payment upon advancement ... patients with compromised kidney function. Isis is also eligible ...
(Date:5/4/2015)... , May 4, 2015  FireflySci Inc., the newest member of the cuvette manufacturing ... they have turned the cuvette industry on its head by offering scientists amazing support for their ... Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
Breaking Medicine Technology:Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3
... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... with operations in China and the United States, today ... second quarter of 2011 after the New York Stock ... be Thursday morning, August 11, 2011 Shanghai time). The ...
... RAPIDS, Mich., July 19, 2011 ... rehabilitation and software services that benefit patients, healthcare ... to its multi-state group of outpatient clinics.  Agility ... the Company,s Michigan-based outpatient clinic presence to 23 ...
Cached Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release 2Agility Health Expands National Outpatient Clinic Group with New Michigan Facility 2
Sebia's Hb AFSC Control provides excellent resolution of normal hemoglobins A & F and abnormal hemoglobins S & C. The control is designed for use with Sebia's Hydragel Hemoglobin and Hydragel Acid He...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity ...
Inquire...
Medicine Products: